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T
Xduration of support with the HeartMate II LVAD does not
affect posttransplant survival, unlike the earlier experience
with patients supported with pulsatile devices.
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Dr James K. Kirklin (Birmingham, Ala). I have no financial
disclosures to make.
I congratulate the authors on a very nice analysis of the Heart-
Mate II experience as BTT therapy. This reflects the changing land-
scape that is occurring in mechanical support as the vast majority of
devices now implanted are these smaller rotary pumps.
My first question relates to driveline infection. As we know, the
major Achilles’ heel of this pump and others like it is the ongoing
low risk, which continues to be constant over time, of driveline in-
fections developing. You showed some potentially important infor-
mation in that even though the P value was .07, the 75% 1-year
survival associated with patients who had driveline infections
was perhaps important. In view of that, do you have plans to go
back and specifically review the causes of death in that cohort of
patients so that we can better clarify this issue?
Dr John. That is an important question. Yes, we do plan to.
Luckily it is a small number of patients, about 14 or 15, and we
should be able to track that down. It would be important to identify
whether these posttransplant deaths were specifically related to in-
fection and, even more importantly, whether the microbiologic
studies performed in these patients who may have died of sepsis
showed that the bacteria identified were similar to the original bac-
teria isolated at the time of driveline infections.
I think the take-home message is that patients with driveline in-
fections should be adequately treated with long-term intravenous
antibiotic therapy before transplantation, and many of these pa-
tients in our experience need maintenance therapy with oral antibi-
otics until the time of transplantation, even though their driveline
infection seems to be eradicated.
Dr Kirklin.My second and final question relates to duration of
LVAD support. Your data indicate and you conclude that the dura-
tion of LVAD support no longer has any influence on posttrans-
plant survival, and this obviously has important implications. I
am still not totally comfortable with your analysis and yourery c July 2010
John et al Cardiothoracic Transplantationconclusions in that there was a small decrease, although nonsignif-
icant, in survival for those patients who were supported greater than
6 months. Furthermore, most of these were basically univariate
analyses.
Do you think it would be advisable to now go back and do
a more detailed multivariable analysis looking at duration of sup-
port as a continuous variable and at possible interactions with other
risk factors before concluding securely that extended LVAD sup-
port has no impact on intermediate-term or long-term survival after
transplant? To follow up on that, on the basis of your analysis,
would you currently recommend that the priority status for LVADs
in obtaining donor hearts be eliminated because of your conclusion
that there is no impact on duration and survival?
Dr John. Thank you. Those are very important comments. With
increasing duration of LVAD support, 2 other variables occur with
increased frequency in patients supported for longer than 6 months.
First, there is an increasing incidence of driveline infections the lon-
ger patients are receiving LVAD support. Second, patients who are
waiting a long time on LVAD support may be waiting because they
are sensitized. The increased incidence of both of these variables
may account for the slight decrease in posttransplant survival
when patients are on LVAD support for longer durations. It is im-
portant, therefore, to do a multivariate analysis to identify the clin-
ically significant variables—infection, sensitization, increased
duration, or a combination of these risk factors.
Currently, patients on LVAD support are usually assigned 1B
status on the UNOS list and then get upgraded to a 1A status for
a 1-month period after LVAD implantation. Most centers choose
the timing of the upgrade to a 1A status around the 2- to 6-month
mark, depending on blood group, regional based waiting times,
as well as clinical patient-related variables. As reported in this
study, the median duration of support for LVAD patients beforeThe Journal of Thoracic and Catransplantation is about 150 days. This might suggest that there
may be support for removal of the 1A status for a stable LVAD pa-
tient and only allow the special status of 1A for LVAD patients who
are experiencing an adverse complication such as infection, severe
arrhythmias, or sensitization. I think upgrading to a 1A status for
a stable LVAD patient at home who is doing clinically well comes
into question, in light of the increasing durability of currently avail-
able LVADs.
Dr Kirklin. Very nice analysis. Thank you.
Dr Stephen J. Lahey (Brooklyn, NY). I was very interested to
see that one of your adverse risk factors was blood transfusions.
This is a very interesting topic, not just in your particular area
but in all of cardiac surgery. Multiple groups, such as the Northern
New England Consortium, have reported that blood transfusions
are a very, very bad thing and do predict mortality. Perhaps it would
it be helpful if we had some idea of the triggers for transfusion. You
have 33 centers. There may be some centers that will transfuse at
a hematocrit value of 24% or others at a hematocrit value of
28%. This fact, in and of itself, can be a confounder as far as using
‘‘blood transfusion’’ as an adverse risk predictor.
Dr John. I agree. Our general policy at our center is to delay
blood transfusions for as long as possible, even up to a hemoglobin
value of 8 g, because these patients could get sensitized with the
next unit of blood, but that information is important. Unfortunately,
that trigger is not going to be obtained because of the number of
centers and variable triggers for each center. But that is important
information, I agree.
Dr David H. Adams (New York, NY). I do not know whether
you know the age of your transfusion, but a paper published last
year from Cleveland showed the age of blood products also nega-
tively affected survival, and it may be something worth looking at
as well.rdiovascular Surgery c Volume 140, Number 1 181
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